Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:VRP
- CUSIP: N/A
- Web: N/A
- Market Cap: £78.33 million
- Outstanding Shares: 51,361,000
- 50 Day Moving Avg: GBX 135.69
- 200 Day Moving Avg: GBX 151.59
- 52 Week Range: GBX 120.77 - GBX 210
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.67 per share
- Price / Book: 2.28
- Average Volume: 24,690 shs.
Frequently Asked Questions for Verona Pharma Plc (LON:VRP)
What is Verona Pharma Plc's stock symbol?
Verona Pharma Plc trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
Where is Verona Pharma Plc's stock going? Where will Verona Pharma Plc's stock price be in 2017?
4 brokerages have issued 12 month price targets for Verona Pharma Plc's shares. Their forecasts range from GBX 22 to GBX 250. On average, they expect Verona Pharma Plc's share price to reach GBX 80.75 in the next year. View Analyst Ratings for Verona Pharma Plc.
Who are some of Verona Pharma Plc's key competitors?
Some companies that are related to Verona Pharma Plc include Charles Taylor PLC (CTR), Atalaya Mining PLC (ATYM), STV Group Plc. (STVG), Amino Technologies Plc (AMO), Carpetright plc (CPR), Walker Greenbank plc (WGB), Finsbury Food Group plc (FIF), Atalaya Mining PLC (EMED), OPG Power Ventures Plc. (OPG), Firestone Diamonds PLC (FDI), RM plc (RM), Pantheon Resources Plc (PANR), Draper Esprit PLC (GROW), Frontier Developments PLC (FDEV), SQS Software Quality Systems AG (SQS), Maintel Holdings plc (MAI), Aminex plc (AEX) and Zotefoams plc (ZTF).
How do I buy Verona Pharma Plc stock?
Shares of Verona Pharma Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Verona Pharma Plc stock cost?
One share of Verona Pharma Plc stock can currently be purchased for approximately GBX 152.50.
Earnings History for Verona Pharma Plc (LON:VRP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Verona Pharma Plc (LON:VRP)
Current Year EPS Consensus Estimate: $-38.15 EPS
Dividend History for Verona Pharma Plc (LON:VRP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Verona Pharma Plc (LON:VRP)Insider Trades by Quarter for Verona Pharma Plc (LON:VRP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/27/2017||David Ebsworth||Insider||Buy||177,776||GBX 169||£300,441.44|
|4/26/2017||David Ebsworth||Insider||Buy||13,373||GBX 132||£17,652.36|
|3/1/2017||Sven Jan-Anders Karlsson||Insider||Buy||7,750||GBX 149||£11,547.50|
|2/28/2017||Sven Jan-Anders Karlsson||Insider||Buy||12,000||GBX 149||£17,880|
|8/9/2016||Jan-Anders Karlsson,Sven||Insider||Buy||600,000||GBX 3||£18,000|
|6/17/2015||David Ebsworth||Insider||Buy||250,000||GBX 4.70||£11,750|
|5/18/2015||David Ebsworth||Insider||Buy||300,000||GBX 3.50||£10,500|
|3/3/2015||David Ebsworth||Insider||Buy||450,000||GBX 2.43||£10,935|
|2/16/2015||Biresh Roy||Insider||Buy||500,000||GBX 2.30||£11,500|
|2/13/2015||Sven Jan-Anders Karlsson||Insider||Buy||1,025,909||GBX 2||£20,518.18|
|2/4/2015||David Ebsworth||Insider||Buy||700,000||GBX 1.54||£10,780|
|1/19/2015||Stuart Bottomly||Insider||Buy||1,000,000||GBX 1.50||£15,000|
|1/13/2015||David Ebsworth||Insider||Buy||803,107||GBX 1.35||£10,841.94|
Headline Trends for Verona Pharma Plc (LON:VRP)
Latest Headlines for Verona Pharma Plc (LON:VRP)
Verona Pharma Plc (VRP) Chart for Friday, May, 26, 2017